Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 2Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Burkitt Lymphoma 1

Interventions

Dexamethasone 8Cytarabine 7Cyclophosphamide 7venetoclax 6Vincristine 6Methotrexate 5merphos 4Rituximab 4Prednisone 4pegaspargase 3fludarabine phosphate 3dexamethasone acetate 3dexamethasone 21-phosphate 3Peripheral Blood Stem Cell Transplantation 3Filgrastim 3Calcium Dobesilate 3ruxolitinib 2prednylidene 2nelarabine 2deltacortene 2auricularum 2Whole-Body Irradiation 2Specimen Handling 2Pentetic Acid 2Mycophenolic Acid 2Injections 2Granulocyte Colony-Stimulating Factor 2Everolimus 2Etoposide 2Decitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × azathiopurine × Clear all
NCT05032183 2025-08-11

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
4 enrolled 8 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡